Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24581831 | 0.84 | ALDH1A1 (0.35) | NFKB1NFKB2RELAALDH1A1KMT2A | |
| SCHEMBL24576800 | 0.84 | ALDH1A1 (0.35) | NFKB1NFKB2RELAALDH1A1KMT2A | |
| SCHEMBL20198054 | 0.82 | ELANE (0.37) | MAPT | |
| SCHEMBL20048752 | 0.79 | AAK1 (0.36) | ALDH1A1KMT2A | |
| SCHEMBL18720298 | 0.78 | MGLL (0.30) | — | |
| SCHEMBL14058311 | 0.78 | NFKB1 (0.36) | NFKB1NFKB2RELAALDH1A1KMT2A | |
| SCHEMBL8131477 | 0.77 | RAB9A (0.36) | NFKB1NFKB2RELAALDH1A1KMT2A | |
| SCHEMBL18720309 | 0.77 | — | — | |
| SCHEMBL357401 | 0.76 | KDM4E (0.42) | ALDH1A1KMT2AGAAMAPT | |
| SCHEMBL6890388 | 0.76 | KDM4E (0.42) | ALDH1A1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229280-A | Method for preparing capromorelin | 洛阳惠中兽药有限公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2024217441-A1 | GHSR 1A AGONIST, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-117229280-A | Method for preparing capromorelin | 洛阳惠中兽药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-2852591-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5]DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | Novartis AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20130331369-A1 | 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists | NOVARTIS AG (CH) | 2013-12-12 | — | — | US | disclosed |
| US-20130296358-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| WO-2013164790-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5 ] DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-8546416-B2 | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| WO-2012164473-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20120302540-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| WO-1998058949-A1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PRODUCTS INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998058947-A1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0869968-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0828754-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1996038471-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996035713-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER, INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0186292-B1 | TRIPEPTIDES AND SWEETENING AGENTS CONTAINING THE SAME | AJINOMOTO CO., INC. (JP) | 1990-05-16 | — | — | EP | disclosed |
| US-4780528-A | Tripeptides and sweetening agents containing the same | AJINOMOTO CO., INC. (JP) | 1988-10-25 | — | — | US | disclosed |
| EP-0186292-A2 | Tripeptides and sweetening agents containing the same | AJINOMOTO CO., INC. (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331369-A1 | 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists | GIPR, GHSR, GLP1R | NFKB1 2215/4885NFKB2 2467/4885RELA 1609/4885 |
| US-20130296358-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GIPR, GHSR, GLP1R | NFKB1 2215/4885NFKB2 2467/4885RELA 1609/4885 |
| US-20120302540-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GIPR, GHSR, GLP1R | NFKB1 2215/4885NFKB2 2467/4885RELA 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.